How CBD Might Work Against Seizures: A Computational Study

Computational study using ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) analysis and molecular docking simulations. Targets were selected based on their established roles in epilepsy: CaV T-type, GABA-A, KCNQ2, NaV, and AMPA receptors. Compounds identified through HPLC analysis were docked against 5IKQ and 3RP8 enzyme structures.

Despite CBD's FDA approval for certain epilepsies (as Epidiolex), the precise mechanisms by which it reduces seizures remain incompletely understood. This computational work maps potential receptor interactions that could explain CBD's broad-spectrum anti-seizure activity and its known drug interactions — providing targets for future experimental validation.

This connects to the broader epilepsy cluster in this database. Clinical studies have established that CBD reduces seizures in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis (RTHC-00160, RTHC-00165, RTHC-00186, RTHC-00189, RTHC-00190). This computational work attempts to explain why CBD works across such different epilepsy types — potentially because it acts on multiple receptor systems simultaneously rather than a single target.

Computational modeling predicts possible interactions but does not confirm they occur in living systems. Molecular docking scores indicate binding potential, not biological activity. In silico ADMET parameters may not match real pharmacokinetics. Results require experimental validation in cell and animal models.